Despite reported immuno-suppressive effects [6, 7], Sorafenib has also been shown to reduce the proportion of PD-1-expressing CD8+ T cells within the tumor microenvironment in orthotopic HCC mice [8]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.